NSCLC Treatment: MET Exon 14 Skipping Mutations and RET Rearrangements

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Zidesamtinib elicited positive activity in patients with advanced ROS1-positive NSCLC who previously received a ROS1 TKI in the phase 1/2 ARROS-1 trial.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The regulatory decision regarding the subcutaneous pembrolizumab formulation is based on results from the phase 3 3475A-D77 trial.

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.